AngioDynamics (NASDAQ:ANGO) Shares Gap Up Following Better-Than-Expected Earnings

Posted by Brian Himes on Jul 14th, 2026

AngioDynamics, Inc. (NASDAQ:ANGO – Get Free Report)’s share price gapped up before the market opened on Tuesday following a better than expected earnings announcement. The stock had previously closed at $12.77, but opened at $13.64. AngioDynamics shares last traded at $12.69, with a volume of 75,522 shares trading hands.

The medical instruments supplier reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.04. The business had revenue of $86.61 million for the quarter, compared to analyst estimates of $80.24 million. AngioDynamics had a negative net margin of 10.01% and a negative return on equity of 4.66%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS.

Wall Street Analyst Weigh In

ANGO has been the topic of a number of recent research reports. Freedom Capital raised AngioDynamics to a “strong-buy” rating in a research note on Monday, April 6th. Canaccord Genuity Group cut their target price on AngioDynamics from $18.00 to $16.00 and set a “buy” rating for the company in a research note on Monday, April 6th. Zacks Research lowered AngioDynamics from a “strong-buy” rating to a “hold” rating in a report on Monday, March 30th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, AngioDynamics has an average rating of “Moderate Buy” and an average price target of $18.67.

View Our Latest Research Report on AngioDynamics

Hedge Funds Weigh In On AngioDynamics

Several large investors have recently modified their holdings of the business. Divisadero Street Capital Management LP increased its position in shares of AngioDynamics by 8.3% during the 3rd quarter. Divisadero Street Capital Management LP now owns 3,678,125 shares of the medical instruments supplier’s stock worth $41,085,000 after purchasing an additional 282,695 shares during the last quarter. Millennium Management LLC boosted its stake in AngioDynamics by 28.1% during the third quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock worth $20,030,000 after buying an additional 393,682 shares during the period. Kotler Kevin purchased a new position in AngioDynamics during the fourth quarter worth about $21,997,000. Armistice Capital LLC increased its position in shares of AngioDynamics by 3.9% during the fourth quarter. Armistice Capital LLC now owns 1,700,000 shares of the medical instruments supplier’s stock valued at $21,828,000 after acquiring an additional 64,000 shares during the last quarter. Finally, Weber Capital Management LLC ADV acquired a new stake in shares of AngioDynamics during the fourth quarter valued at about $17,978,000. Institutional investors and hedge funds own 89.43% of the company’s stock.

AngioDynamics Stock Performance

The business’s 50 day moving average price is $12.03 and its 200-day moving average price is $11.32. The firm has a market capitalization of $516.09 million, a PE ratio of -16.65 and a beta of 0.34.

About AngioDynamics

(Get Free Report)

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.